Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: A retrospective study

Objective: Multiple myeloma remains incurable and retreatment with available therapies is of substantial interest. Methods: This retrospective observational study included data from 35 patients treated initially and at the first relapse with bortezomib-containing regimens. Results: Bortezomib retreatment provided a similar depth and time to response as first-line therapy; however, as could be expected, the duration of response was shorter with retreatment. The tolerability profile was similar with bortezomib as the first- and second-line therapy, with no evidence of cumulative toxicity. Conclusion: These findings support bortezomib retreatment after a treatment-free interval of ≥6 months in patients who achieved at least a partial response to the first-line bortezomib-based therapy.